Liraglutide on type 2 diabetes mellitus with nonalcoholic fatty liver disease: A systematic review and meta-analysis of 16 RCTs.

Zhao Y, Zhao W, Bu H, Toshiyoshi M, Zhao Y

Medicine1 Feb 2023Cited by 9 (Europe PMC)

PMID36820578PMCIDPMC9907937DOI10.1097/md.0000000000032892PepBankPUB-36820578

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes and NAFLD, 14 of 16 trials showed lower fasting plasma glucose with liraglutide than with control.
In plain wordsIn adults with type 2 diabetes and fatty liver, most trials found lower fasting blood sugar with liraglutide than with control.
Peptide
Liraglutide
Outcome
DecreaseFasting plasma glucose
Study
n: not reported in source
Comparator
Control group
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
14 studies show that fasting plasma glucose levels of the experimental group are lower than that of the control group
1 context sentence(design, population, supporting numbers)
Summary · context
Sixteen studies are selected for this meta-analysis, which includes totally 634 patients in the treatment group and 630 patients in the control group.
Report a problemFND-3682057801
02HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes and NAFLD, 15 of 16 trials showed lower HbA1c with liraglutide than with control.
In plain wordsIn adults with type 2 diabetes and fatty liver, most trials found lower HbA1c with liraglutide than with control.
Peptide
Liraglutide
Outcome
DecreaseHbA1c
Study
n: not reported in source
Comparator
Control group
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
15 studies show that glycosylated hemoglobin A1c levels of the experimental group are lower than that of the control group
1 context sentence(design, population, supporting numbers)
Summary · context
Sixteen studies are selected for this meta-analysis, which includes totally 634 patients in the treatment group and 630 patients in the control group.
Report a problemFND-3682057802
03HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes and NAFLD, 13 trials showed lower triglycerides with liraglutide than with control.
In plain wordsIn adults with type 2 diabetes and fatty liver, most trials found lower triglycerides with liraglutide than with control.
Peptide
Liraglutide
Outcome
DecreaseTriglycerides
Study
n: not reported in source
Comparator
Control group
Outcome group
Lipids · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
13 studies show that triglyceride levels of the experimental group are lower than that of the control group
1 context sentence(design, population, supporting numbers)
Summary · context
Sixteen studies are selected for this meta-analysis, which includes totally 634 patients in the treatment group and 630 patients in the control group.
Report a problemFND-3682057803
04HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes and NAFLD, twelve trials showed lower total cholesterol with liraglutide than with control.
In plain wordsIn adults with type 2 diabetes and fatty liver, many trials found lower total cholesterol with liraglutide than with control.
Peptide
Liraglutide
Outcome
DecreaseTotal cholesterol
Study
n: not reported in source
Comparator
Control group
Outcome group
Lipids · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
twelve studies show that total cholesterol levels of the experimental group are lower than that of the control group
1 context sentence(design, population, supporting numbers)
Summary · context
Sixteen studies are selected for this meta-analysis, which includes totally 634 patients in the treatment group and 630 patients in the control group.
Report a problemFND-3682057804
05HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes and NAFLD, 10 trials showed lower alanine aminotransferase with liraglutide than with control.
In plain wordsIn adults with type 2 diabetes and fatty liver, some trials found lower ALT liver enzyme levels with liraglutide than with control.
Peptide
Liraglutide
Outcome
DecreaseAlanine aminotransferase
Study
n: not reported in source
Comparator
Control group
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated
Source sentences
Summary
10 studies show that alanine aminotransferase levels of the experimental group is lower than that of the control group
1 context sentence(design, population, supporting numbers)
Summary · context
Sixteen studies are selected for this meta-analysis, which includes totally 634 patients in the treatment group and 630 patients in the control group.
Report a problemFND-3682057805
06HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes and NAFLD, 10 trials showed no significant difference in aspartate transaminase change between liraglutide and control.
In plain wordsIn adults with type 2 diabetes and fatty liver, some trials found no difference in AST liver enzyme change between liraglutide and control.
Peptide
Liraglutide
Outcome
No significant changeAspartate transaminase
Study
n: not reported in source
Comparator
Control group
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated
Source sentences
Summary
10 studies show that no significant difference in changes in aspartate transaminase between 2 groups
1 context sentence(design, population, supporting numbers)
Summary · context
Sixteen studies are selected for this meta-analysis, which includes totally 634 patients in the treatment group and 630 patients in the control group.
Report a problemFND-3682057806
07HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes and NAFLD, 13 trials showed lower LDL cholesterol with liraglutide than with control.
In plain wordsIn adults with type 2 diabetes and fatty liver, most trials found lower LDL cholesterol with liraglutide than with control.
Peptide
Liraglutide
Outcome
DecreaseLDL cholesterol
Study
n: not reported in source
Comparator
Control group
Outcome group
Lipids · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
13 studies show that low density lipoprotein cholesterol levels of the experimental group is lower than that of the control group
1 context sentence(design, population, supporting numbers)
Summary · context
Sixteen studies are selected for this meta-analysis, which includes totally 634 patients in the treatment group and 630 patients in the control group.
Report a problemFND-3682057807
08HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes and NAFLD, 9 trials showed no significant difference in HDL cholesterol change between liraglutide and control.
In plain wordsIn adults with type 2 diabetes and fatty liver, some trials found no difference in HDL cholesterol change between liraglutide and control.
Peptide
Liraglutide
Outcome
No significant changeHDL cholesterol
Study
n: not reported in source
Comparator
Control group
Outcome group
Lipids · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
9 studies show that no significant difference in changes in high density lipoprotein cholesterol between 2 groups
1 context sentence(design, population, supporting numbers)
Summary · context
Sixteen studies are selected for this meta-analysis, which includes totally 634 patients in the treatment group and 630 patients in the control group.
Report a problemFND-3682057808
09HumanSystematic reviewSafety outcome
In adults with type 2 diabetes and NAFLD, 7 trials reported adverse effects, with a significant difference between liraglutide and control; the direction is not stated.
In plain wordsIn adults with type 2 diabetes and fatty liver, 7 trials reported side effects that differed significantly between liraglutide and control.
Peptide
Liraglutide
Outcome
Direction not reportedAdverse effects
Study
n: not reported in source
Comparator
Control group
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated
Source sentences
Summary
7 studies mentioned adverse effects and the difference is significant.
1 context sentence(design, population, supporting numbers)
Summary · context
Sixteen studies are selected for this meta-analysis, which includes totally 634 patients in the treatment group and 630 patients in the control group.
Report a problemFND-3682057809

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.